![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsors and Collaborators: |
VU University Medical Center DSM Food Specialties Leiden University Medical Center |
---|---|
Information provided by: | VU University Medical Center |
ClinicalTrials.gov Identifier: | NCT00810654 |
Oral supplementation with enzymes that can cut gluten has been suggested as a potential treatment modality for coeliac disease. In the present study the investigators wish to determine if co-administration of such an enzyme, a prolyl endoprotease derived from the food grade organism Aspergillis niger (AN-PEP), is capable of detoxifying 8 grams of gluten in a commercial food product.
Condition | Intervention | Phase |
---|---|---|
Celiac Disease |
Dietary Supplement: Aspergillus niger prolyl endoprotease Dietary Supplement: Placebo |
Phase I Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Efficacy Study |
Official Title: | Study on The Effectiveness of Oral Administration of Prolyl Endoprotease for Gluten Detoxification as a Means to Treat Coeliac Disease |
Estimated Enrollment: | 14 |
Study Start Date: | May 2008 |
Estimated Study Completion Date: | May 2009 |
Estimated Primary Completion Date: | February 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
ANPEP: Experimental
Aspergillus niger prolyl endoprotease (AN-PEP), a microbial-derived prolyl endoprotease which cleaves gluten
|
Dietary Supplement: Aspergillus niger prolyl endoprotease
160 PPU daily for 2 weeks
|
Placebo: Placebo Comparator |
Dietary Supplement: Placebo
Placebo
|
The objective of the study is to determine whether AN-PEP enzyme is effective in mitigating the effects of 8 g wheat protein ingestion in patients with celiac disease.
Fourteen patients with coeliac disease, 18-70 years old are recruited. During the first period, patients consume once daily a gluten-containing food product with the AN-PEP enzyme for 2 weeks. After a 2-week washout period (second period), patients enter the third period of this study, and are randomized to one of two groups and consume the same gluten-containing food product with AN-PEP or placebo.
Period 1: Patients are given a food product containing 8 g of wheat protein, to which AN-PEP is added, once daily for 14 d.
Period 2: Wash-out period of 14 d. During this period, patients will consume a gluten-free diet.
Period 3: Patients who are negative for coeliac disease symptoms during the 1st period will be randomized across two groups. Both groups receive a food product containing 8 g of wheat protein once daily for 14 d. One group receives additional AN-PEP with the gluten meal whereas the other group receives the placebo.
Patients will visit the outpatient clinic five times; one visit before the start of the study, a visit during and at the end of the first period, and a visit during and at the end of the third period. During three of the visits, spike-biopsies are taken from the duodenum by oesophago-gastro-duodenoscopy.
Blood samples are taken during all of the five visits. Patients will also fill in a quality of life questionnaire at the start and the end of the first and third period.
Ages Eligible for Study: | 18 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contact: Chris JJ Mulder, MD, PhD. | +31204440613 | cjmulder@vumc.nl |
Netherlands | |
VU University Medical Center | Recruiting |
Amsterdam, Netherlands, 1081 HV | |
Contact: Chris J Mulder, MD, PhD +31204440613 cjmulder@vumc.nl | |
Sub-Investigator: Jolanda M.W van de Water, MD |
Principal Investigator: | Greetje J Tack, MD | VU University Medical Center |
Responsible Party: | VU University Medical Center ( C.J.Mulder ) |
Study ID Numbers: | RD.0601.54, NTR1281 |
Study First Received: | December 17, 2008 |
Last Updated: | January 21, 2009 |
ClinicalTrials.gov Identifier: | NCT00810654 History of Changes |
Health Authority: | Netherlands: Independent Ethics Committee |
Celiac disease Coeliac disease treatment |
AN-PEP prolyl endoprotease gluten |
Metabolic Diseases Digestive System Diseases Gastrointestinal Diseases Malabsorption Syndromes |
Celiac Disease Intestinal Diseases Metabolic Disorder |
Metabolic Diseases Digestive System Diseases Gastrointestinal Diseases |
Malabsorption Syndromes Celiac Disease Intestinal Diseases |